{
  "thesis_id": "P5",
  "role": "scenario_branch",
  "findings": "Created three scenario branches for the thesis: base (scale-up remains a persistent but manageable bottleneck), upside (scale-up proves a severe binding constraint, validating the thesis), and downside (scale-up bottlenecks are solved or sidestepped, falsifying the thesis). Each branch is linked to the kill condition, forecast clause, and key metrics, and is assigned verification tasks to track unfolding evidence.",
  "proposed_nodes": [
    {
      "id": "n-scenario-branch-p5-base-scale-up-remains-a-persistent-but-manageable-bottleneck-some-ai-designed-products-reach-pilot-scale-but-commodity-scale-limited-fermentation-capacity-expands-but-tight-causing-delays-not-kills-2a3f41e5",
      "kind": "scenario_branch",
      "label": "Base: Scale-up remains persistent but manageable; some AI-designed products reach pilot, but commodity scale is limited; capacity tight, causing delays.",
      "description": "By 2030, a handful of AI-designed bio-products reach pilot or small commercial scale, but commodity-relevant scale (>10,000 tons/year and price parity) is rare. Pilot fermentation and downstream capacity remains constrained, causing delays and cost overruns. Some offtake contracts are signed at premium prices, but few achieve true price parity without sustainability subsidies. The kill condition is not triggered because scale-up bottlenecks are evident, though not catastrophic. The thesis holds marginally.",
      "confidence": 0.65,
      "probability_weight": 0.5,
      "related_thesis_id": "P5"
    },
    {
      "id": "n-scenario-branch-p5-upside-scale-up-proves-a-severe-binding-constraint-multiple-well-funded-ai-bio-companies-fail-or-delay-due-to-pilot-capacity-downstream-bottlenecks-only-niche-high-margin-products-succeed-of-1a5e3b2c",
      "kind": "scenario_branch",
      "label": "Upside: Severe scale-up bottleneck; many failures; only niche high-margin products succeed; thesis strongly confirmed.",
      "description": "By 2030, multiple high-profile AI-bio ventures (e.g., alternative proteins, bio-chemicals, bio-materials) publicly fail or delay scale-up due to insufficient pilot fermentation capacity, downstream processing challenges, and process-development labor shortages. Even well-funded companies cannot secure enough pilot slots, causing 2-3 year delays and cost overruns that make commodity price parity impossible. The kill condition is not met: no AI-designed industrial bio-product reaches commodity-relevant scale and price parity without scarce pilot capacity becoming a public bottleneck. The thesis is vindicated; scale-up remains the dominant binding constraint.",
      "confidence": 0.55,
      "probability_weight": 0.3,
      "related_thesis_id": "P5"
    },
    {
      "id": "n-scenario-branch-p5-downside-breakthroughs-in-scale-up-technologies-overcome-historical-bottlenecks-multiple-ai-designed-products-reach-commodity-scale-price-parity-rapidly-pilot-capacity-expands-sufficiently-df3c7a29",
      "kind": "scenario_branch",
      "label": "Downside: Scale-up solved or sidestepped; multiple AI-designed products reach commodity scale and price parity; thesis falsified.",
      "description": "By 2030, at least two AI-designed industrial bio-products (e.g., a bio-based monomer, enzyme, or cultivated protein) achieve >10,000 tonnes/year production and market price parity with incumbent petroleum or agricultural commodities, without public bottlenecks in pilot capacity or downstream processing. Enabling factors: a breakthrough in continuous bioprocessing, cell-free systems, or AI-driven process optimization dramatically reduces scale-up complexity and cost; pilot capacity expands globally (e.g., through modular, shared facilities); and downstream purification becomes commoditized. The kill condition is triggered, and the thesis is falsified.",
      "confidence": 0.5,
      "probability_weight": 0.2,
      "related_thesis_id": "P5"
    }
  ],
  "proposed_edges": [
    {
      "src": "n-scenario-branch-p5-base-scale-up-remains-a-persistent-but-manageable-bottleneck-some-ai-designed-products-reach-pilot-scale-but-commodity-scale-limited-fermentation-capacity-expands-but-tight-causing-delays-not-kills-2a3f41e5",
      "dst": "n-thesis-p5-biomanufacturing-s-bottleneck-is-scale-up-not-ai-organism-design-fdaccd13",
      "rel": "branches_from_thesis",
      "rationale": "This scenario explores a moderate outcome for the thesis.",
      "confidence": 0.8,
      "verification_status": "derived_from_board"
    },
    {
      "src": "n-scenario-branch-p5-upside-scale-up-proves-a-severe-binding-constraint-multiple-well-funded-ai-bio-companies-fail-or-delay-due-to-pilot-capacity-downstream-bottlenecks-only-niche-high-margin-products-succeed-of-1a5e3b2c",
      "dst": "n-thesis-p5-biomanufacturing-s-bottleneck-is-scale-up-not-ai-organism-design-fdaccd13",
      "rel": "branches_from_thesis",
      "rationale": "This scenario aligns with and confirms the thesis.",
      "confidence": 0.8,
      "verification_status": "derived_from_board"
    },
    {
      "src": "n-scenario-branch-p5-downside-breakthroughs-in-scale-up-technologies-overcome-historical-bottlenecks-multiple-ai-designed-products-reach-commodity-scale-price-parity-rapidly-pilot-capacity-expands-sufficiently-df3c7a29",
      "dst": "n-thesis-p5-biomanufacturing-s-bottleneck-is-scale-up-not-ai-organism-design-fdaccd13",
      "rel": "branches_from_thesis",
      "rationale": "This scenario contradicts and would kill the thesis.",
      "confidence": 0.8,
      "verification_status": "derived_from_board"
    },
    {
      "src": "n-scenario-branch-p5-downside-breakthroughs-in-scale-up-technologies-overcome-historical-bottlenecks-multiple-ai-designed-products-reach-commodity-scale-price-parity-rapidly-pilot-capacity-expands-sufficiently-df3c7a29",
      "dst": "n-kill-condition-kill-if-by-2030-multiple-ai-designed-industrial-bio-products-reach-commodity-relevant-scale-and-price-parity-without-scarce-pilot-capacity-downstream-processing-or-process-development-labor-becoming-a-public-bottleneck",
      "rel": "triggers_kill_condition",
      "rationale": "This downside scenario directly satisfies the kill condition of the forecast clause.",
      "confidence": 0.9,
      "verification_status": "derived_from_board"
    },
    {
      "src": "n-metric-track-ai-designed-or-engineered-bio-products-that-fail-or-delay-on-cogs-and-scale-up",
      "dst": "n-scenario-branch-p5-upside-scale-up-proves-a-severe-binding-constraint-multiple-well-funded-ai-bio-companies-fail-or-delay-due-to-pilot-capacity-downstream-bottlenecks-only-niche-high-margin-products-succeed-of-1a5e3b2c",
      "rel": "monitored_in_scenario",
      "rationale": "This metric tracks failure/delay signals that would appear in the upside scenario.",
      "confidence": 0.7,
      "verification_status": "derived_from_board"
    },
    {
      "src": "n-metric-track-pilot-fermentation-capacity-downstream-bottlenecks-and-offtake-contracts-tied-to-price-parity",
      "dst": "n-scenario-branch-p5-base-scale-up-remains-a-persistent-but-manageable-bottleneck-some-ai-designed-products-reach-pilot-scale-but-commodity-scale-limited-fermentation-capacity-expands-but-tight-causing-delays-not-kills-2a3f41e5",
      "rel": "monitored_in_scenario",
      "rationale": "This metric would show tightness and premium offtakes, consistent with the base scenario.",
      "confidence": 0.7,
      "verification_status": "derived_from_board"
    }
  ],
  "verification_tasks": [
    {
      "id": "vt-p5-scenario-base-evid-001",
      "task": "Track public announcements of AI-designed bio-products that reach pilot scale but are delayed or fail to reach commodity scale by 2028–2030 due to pilot capacity, downstream bottlenecks, or COGS.",
      "evidence_required": "source_url, source_date, product name, scale achieved, reason for delay/failure, statement from company or partners.",
      "owner_agent": "A11",
      "priority": "high"
    },
    {
      "id": "vt-p5-scenario-upside-evid-002",
      "task": "Monitor trade press and investor communications for instances where well-funded synbio startups explicitly cite inability to secure pilot fermentation runs as a major barrier to scaling.",
      "evidence_required": "source_url, source_date, quote mentioning 'pilot capacity shortage' or 'fermentation bottleneck'.",
      "owner_agent": "A11",
      "priority": "high"
    },
    {
      "id": "vt-p5-scenario-upside-evid-003",
      "task": "Track offtake agreements for AI-designed bio-products; identify whether prices are premium-priced (sustainability premium) or at parity with incumbent commodities.",
      "evidence_required": "source_url, source_date, contract details if public, pricing comparison.",
      "owner_agent": "A11",
      "priority": "medium"
    },
    {
      "id": "vt-p5-scenario-downside-evid-004",
      "task": "Identify announcements of large-scale (10,000+ tonnes/year) commercial production of AI-designed bio-commodities (e.g., chemicals, materials) with explicit price parity claims, and verify whether pilot capacity or downstream processing was cited as a non-bottleneck.",
      "evidence_required": "source_url, source_date
